Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + Ivonescimab + Chemotherapy in Advanced Gastric/GEJ Cancer
NCT06196697Phase 2Recruiting
- Sponsor
- Harbin Medical University
- Start
- Apr 2024
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab, ivonescimab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Harbin Medical University. Started Apr 2024; status: recruiting.
02
Drugs
cadonilimabivonescimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06196697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06196697.